Nachrichten zur Eli Lilly & Co. Aktie

3 Magnificent Growth Stocks to Buy Right Now

In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks…

Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active…

Gileads new HIV med, a bird flu shot for chickens, and Hims does blood tests: Pharma news roundup

Plus, Trump threatens tariffs on pharmaceuticals, and Eli Lilly sets its eyes on preventing Alzheimers…

Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by…

Eli Lilly aims to invest in big problems hiding in plain sight using obesity windfall

Eli Lilly wants to take big swings in Alzheimers, ALS, chronic pain and other difficult diseases after its success in…

From pills to new uses, heres what Eli Lilly’s top scientist sees as the future of weight loss drugs

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight…

Fat, not muscle: drugmakers in race for next weight-loss breakthrough

Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisks Wegovy and Eli Lillys Zepbound result…

The Zacks Analyst Blog Highlights Apple, Eli Lilly, Shopify and ImmuCell

Apple, Eli Lilly, Shopify and ImmuCell are part of the Zacks top Analyst Blog.…

This Company Just Initiated a Quarterly Dividend: Time to Buy?

Biotech giant Renegeron Pharmaceuticals (NASDAQ: REGN) reported its fourth-quarter and full-year 2024 earnings on Feb. 4. The companys results were…

3 Stocks That Could Trounce the Market in 2025

If youre content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not,…

2 Important Insights From Novo Nordisks Earnings Call

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. The Denmark-based company performed…

What’s ahead for Eli Lilly and Novo as RFK Jr. takes over HHS

…

Think Eli Lillys Stock Is Expensive? Heres Why Selling It Now Could Be a Huge Mistake

Investors should never ignore valuations when picking stocks. The price a stock trades at can drastically impact your overall returns.…

Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon

In the GLP-1 weight loss market, its largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO).…

LLY Rises More Than 4% in a Week: How to Play the Stock

Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth…

GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced its full…

Eli Lilly issues $6 billion in new debt securities By Investing.com

Eli Lilly issues $6 billion in new debt securities…

2 Growth Stocks to Buy Hand Over Fist in February

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in…

Notable healthcare headlines for the week: Eli Lilly, Merck and Becton, Dickinson in focus

…

2 Stocks That Could Soar Again in 2025

Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (NASDAQ: VKTX) and…

Lilly Endowment sells $183.6 million in Eli Lilly stock By Investing.com

Lilly Endowment sells $183.6 million in Eli Lilly stock…

Eli Lillys rating gets an upgrade to Aa3 by Moodys Ratings By Investing.com

Eli Lillys rating gets an upgrade to Aa3 by Moodys Ratings…

Lilly expands GLP-1 research to hypertension, neuro conditions

Morning. Today, we have a look at the White Houses reported plans to make major cuts across federal health agencies.…

Eli Lilly Q4: Dont Miss Out On 2025 Gains, Theres Limited Space Left

…

Eli Lilly (LLY) Q4 2024 Earnings Call Transcript

LLY earnings call for the period ending December 31, 2024.…

Eli Lilly has its mojo back ahead of a pivotal year for the obesity drug giant

The drugmaker is not perfect, as the past few months showed, but its still a thoroughbred.…

Why Eli Lilly Stock Popped on Thursday

Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom…

LLYs Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of Estimates

Eli Lilly beats fourth-quarter estimates for earnings and sales. Mounjaro and Zepbound sales miss estimates.…

Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.…

Stocks making the biggest moves premarket: Ford, Eli Lilly, Honeywell, Arm Holdings and more

These are the stocks posting the largest moves in premarket trading.…

Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short

Zepbound and Mounjaro have now underperformed expectations for two straight quarters.…

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

…

Eli Lilly reports mixed earnings, increases 2025 guidance

…

Pharmakonzern Lilly beendet 2024 überraschend stark - Prognose bestätigt

INDIANAPOLIS (dpa-AFX) - Ein florierendes Geschäft mit seinen Diabetes- und Abnehmmitteln hat dem US-Pharmahersteller Lilly 2024…

Lilly forecasts 2025 profit largely above estimates on weight-loss drug strength

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular diabetes…

Eli Lilly revenue misses expectations despite strong growth in Mounjaro, Zepbound

Eli Lilly and Co (NYSE:LLY) reported mixed results for the fourth quarter, with earnings outpacing estimates despite revenue from its…

Eli Lilly Q4 earnings beat as weight loss drug sales miss estimates

Eli Lilly and Co (NYSE:LLY) reported mixed results for the fourth quarter, with earnings outpacing estimates as revenue from its…

Stock futures are little changed after S&P 500 posts back-to-back winning sessions: Live updates

Following a second day of stock market gains, investors looked forward to earnings reports from Eli Lilly and Amazon.…

Eli Lilly must put to rest doubts about whether Zepbounds growth can live up to the hype

Living up to the hype around GLP-1 obesity treatments is tough enough. But Eli Lilly needs to hit its own…

Why Novo Nordisk Stock Is Soaring Today

Shares of Novo Nordisk (NYSE: NVO) were moving higher on Wednesday. The companys stock gained 4.9% as of 1:50 p.m.…

Lilly needs a plan to spur weight-loss drug sales, investors say

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to…

Novo Nordisk Q4 profit beats expectations, sees slower growth in 2025

Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow that is likely to…

The Zacks Analyst Blog Highlights Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb

Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb are included in this Analyst Blog.…

3 Magnificent Stocks to Buy and Hold Forever

Some people are fair-weather friends; others are lifelong. Its a similar story with stocks. Some you might hold only temporarily,…

Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy?

Investor focus is likely to be on the sales numbers of LLYs tirzepatide medicines Mounjaro and Zepbound.…

Here are the 11 things were watching in the stock market in the week ahead

Jobs data and earnings from the likes of Amazon and Eli Lilly take center stage in the week ahead.…

Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to…

With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While thats not much of an issue…

Got $1,000? 2 Top Growth Stocks to Buy Right Now

Being a long-term investor isnt always easy, as youll inevitably encounter downturns as well as the thriving bull periods that…

3 Unstoppable Stocks You Can Buy and Hold for the Rest of Your Life

If you want stocks that you can buy and hold for not only years, but potentially the rest of your…